Definition of treatment-resistant depression - Asia Pacific perspectives

被引:38
|
作者
Ng, C. H. [1 ]
Kato, T. [2 ]
Han, C. [3 ]
Wang, G. [4 ]
Trivedi, M. [5 ]
Ramesh, V. [6 ]
Shao, D. [6 ]
Gala, S. [6 ]
Narayanan, S. [6 ]
Tan, W. [7 ]
Feng, Y. [7 ]
Kasper, S. [8 ]
机构
[1] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia
[2] RIKEN Brain Sci Inst, Saitama, Japan
[3] Korea Univ, Seoul, South Korea
[4] Capital Med Univ, Anding Hosp, Beijing, Peoples R China
[5] Univ Texas Southwestern Med Ctr, Dallas, TX USA
[6] Market Access Solut LLC, Raritan, NJ USA
[7] Janssen Asia Pacific, Singapore, Singapore
[8] Med Univ Vienna, Vienna, Austria
关键词
Treatment resistant depression; Asia-pacific; Definition; Consensus; Systematic literature review; Expert panel; TRANSCRANIAL MAGNETIC STIMULATION; THETA-BURST STIMULATION; ELECTROCONVULSIVE-THERAPY; RANDOMIZED-TRIAL; DOUBLE-BLIND; OPEN-LABEL; FOLLOW-UP; ARIPIPRAZOLE AUGMENTATION; ANTIDEPRESSANT TREATMENT; FUNCTIONAL CONNECTIVITY;
D O I
10.1016/j.jad.2018.11.038
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The lack of uniformity in the definition of treatment resistant depression (TRD) within the Asia-Pacific (APAC) region may have implications for patient management. We aimed to characterize the most commonly used TRD definition in selected APAC countries. Methods: A systematic literature review of TRD definitions in APAC countries was conducted in Medline and Embase (2010-2016) and conference proceedings (2014 and 2016). TRD guidelines (APAC, Europe regional, US, or international) were also searched. An expert-panel explored APAC nuances in TRD definitions to achieve consensus for a regional-level definition. Results: Ten guidelines and 89 studies qualified for study inclusion. Among the studies, variations were observed in definitions regarding: number of antidepressants failed (range: (3) 1 to (3) 3), classes of antidepressants (same or different; 59% did not specify class), duration of previous treatments (range: 4-12 weeks), dosage adequacy, and consideration of adherence (yes/no; 88% of studies did not consider adherence). No TRD-specific guidelines were identified. The emerging consensus from the literature review and panel discussion was that TRD is most commonly defined as failure to (3) 2 antidepressant therapies given at adequate doses, for 6-8 weeks during a major depressive episode. Limitations: Few studies provided definitions of TRD used in daily clinical practice, and a limited number of countries were represented in the included studies and expert panel. Conclusion: Attaining consensus on TRD definition may promote accurate, and possibly early detection of patients with TRD to enable appropriate intervention that may impact patient outcomes and quality of life.
引用
收藏
页码:626 / 636
页数:11
相关论文
共 50 条
  • [21] Management of Treatment-Resistant Depression
    Keitner, Gabor I.
    Mansfield, Abigail K.
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2012, 35 (01) : 249 - +
  • [22] Biological Perspectives Ketamine as an Alternative Treatment for Treatment-Resistant Depression
    Dowben, Jonathan S.
    Grant, Joan S.
    Keltner, Norman L.
    PERSPECTIVES IN PSYCHIATRIC CARE, 2013, 49 (01) : 2 - 4
  • [23] Preclinical models of treatment-resistant depression: challenges and perspectives
    Magdalena Kolasa
    Agata Faron-Górecka
    Pharmacological Reports, 2023, 75 : 1326 - 1340
  • [24] Treatment-resistant depression: Established and emerging therapies
    Mcbroom, Leesa A.
    Timmons, Melissa
    NURSE PRACTITIONER, 2024, 49 (12): : 35 - 40
  • [25] Brain stimulation therapies for treatment-resistant depression
    Vitalucci, Alberto
    Coppola, Isabella
    Mirra, Marta
    Maina, Giuseppe
    Bogetto, Filippo
    RIVISTA DI PSICHIATRIA, 2013, 48 (03) : 175 - 181
  • [26] Efficacy of repetitive transcranial magnetic stimulation in treatment-resistant depression: the evidence thus far
    Somani, Aditya
    Kar, Sujita Kumar
    GENERAL PSYCHIATRY, 2019, 32 (04)
  • [27] Pramipexole and Electroconvulsive Therapy in Treatment-Resistant Depression
    Gauthier, Claire
    Souaiby, Lama
    Advenier-Iakovlev, Emmanuelle
    Gaillard, Raphael
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (06) : 264 - 267
  • [28] Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment
    McKeown, Lucas
    Taylor, Rachael W.
    Day, Elana
    Shah, Rupal
    Marwood, Lindsey
    Tee, Helena
    Kerr-Gaffney, Jess
    Oprea, Emanuella
    Geddes, John R.
    McAllister-Williams, R. Hamish
    Young, Allan H.
    Cleare, Anthony J.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2022, 36 (05) : 557 - 565
  • [29] Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review
    Caldiroli, Alice
    Capuzzi, Enrico
    Tagliabue, Ilaria
    Capellazzi, Martina
    Marcatili, Matteo
    Mucci, Francesco
    Colmegna, Fabrizia
    Clerici, Massimo
    Buoli, Massimiliano
    Dakanalis, Antonios
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [30] Treatment-resistant depression. From classification to new therapies.
    Paganin, Walter
    Signorini, Sabrina
    Leccese, Vincenzo
    Sciarretta, Antonio
    RIVISTA DI PSICHIATRIA, 2022, 57 (06) : 258 - 272